Bio X Cell (BXC), a leader in the development and supply of high-quality products for scientific research, has announced the appointment of Chris Conway as its new Chief Executive Officer. Conway, who most recently served as President of Research and Development (R&D) at Curia, succeeds Klaus Lubbe, the company’s founder, who remains involved as a board member and minority shareholder following the sale of a majority stake to Windjammer Capital Investors in November 2023.
Conway brings a wealth of experience in both small molecule and biologics drug discovery to his new role. Joining Curia (formerly AMRI) in 2008 from Johnson & Johnson, Conway has held a series of significant commercial leadership positions. His career trajectory at Curia saw him advance from Senior Vice President and Drug Discovery and Development Business Unit Head in 2015, to President of the R&D business unit in 2019. Under his leadership, the business experienced notable organic and inorganic growth, managing twenty sites globally.
Klaus Lubbe, who founded Bio X Cell in 1997, expressed confidence in Conway’s appointment. “As my successor, Chris not only brings strong business and industry credentials but also an understanding and respect for Bio X Cell’s culture and mission,” Lubbe stated. He highlighted Conway’s commitment to advancing scientific discovery and innovation, aligning with the company’s goal of providing the highest quality products and exceptional customer service.
Craig Majernik, Managing Director at Windjammer, also endorsed Conway’s appointment. “During his tenure at AMRI/Curia, Chris held diverse leadership roles and helped the business grow as it transitioned from founder-led to private equity ownership,” Majernik noted. He praised Conway’s proven leadership skills, commercial expertise, and extensive reach across the drug development industry, emphasising that these attributes make him well-suited to lead Bio X Cell through its next phase of growth.
Conway himself expressed enthusiasm about the opportunity to lead Bio X Cell. “Bio X Cell’s tremendous brand reputation throughout the global research community, especially within academia and government, is a testament to the care and attention Klaus and his team have brought to the business,” he said. Conway highlighted his intention to build upon Bio X Cell’s strong foundation, continue expanding its high-quality product offerings, and enhance its presence in the commercial sector through both organic growth and strategic acquisitions.
As Conway steps into his new role, the focus will be on leveraging his extensive experience to drive innovation and growth at Bio X Cell, ensuring the company remains at the forefront of advancements in scientific research and continues to meet the evolving needs of its global customer base.
Contributed by: PR Newswire
